Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs Toyota Motor Corp (TM) Price & Performance

Moderna, Inc.Trade
Toyota Motor CorpTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Toyota Motor Corp — how do they compare? Moderna, Inc. trades at $64.05 (market cap $24.18B), while Toyota Motor Corp trades at $188.81 (market cap $221.79B). The key difference: Toyota Motor Corp is far larger — about 9.2× Moderna, Inc.'s market cap, and Toyota Motor Corp pays a 3.3% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

MRNATM
Market Cap
$24.18B$221.79B
Sector
HealthConsumer Cyclical
52-Week High
$81.80$248.29
52-Week Low
$22.36$166.50
Enterprise Value
$20.33B$414.06B
Dividend Yield
3.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Toyota Motor Corp

Toyota Motor trades at $188.54, down 0.13% with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 8.53, P/S of 0.74, and consistent earnings beats in recent quarters. Revenue grew to $48.04T in 2025, though net income margin declined to 8.63%. Recent news includes a major vehicle recall affecting 508,000 US vehicles and a 76% surge in Q1 net profit reported on August 4, 2026.

Toyota presents a mixed outlook with attractive valuation metrics and strong profitability offset by recall-related headwinds and China market weakness. The stock offers value opportunity with below-market multiples, but investors face execution risks from quality control issues and regional sales challenges. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About Toyota Motor Corp

Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.

Read more on TM